Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

NCT02592785 | Completed Phase 1

• 1 other identifier: 16958
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 2

Brief Summary

Primary objectives of this study are to assess the safety and tolerability of BAY 1163877 in Japanese subjects with refractory, locally advanced or metastatic solid tumors and to characterize the PK of BAY 1163877

Conditions

Neoplasms

Outcome Measures

Primary Outcomes (23)

• Number of an Treatment Emergent Adverse Event

  Up to 35 days after the last study drug administration

• Intensity of an Treatment Emergent Adverse Event graded using the NCI-CTCAE version 4.03

  Up tp 35 days after the last study drug administration

• Maximum observed plasma concentration after single dose administration (Cmax) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• Cmax divided by dose (mg) per kg body weight (Cmax,norm) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• Cmax divided by dose (mg) (Cmax/D) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• Area under the plasma concentration vs time curve from zero to 12 hours p.a. after first-dose administration (AUC(0-12)) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose

• AUC(0-12) divided by dose (mg) per kg body weight (AUC(0-12) norm) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose

• AUC(0-12) divided by dose (mg) (AUC(0-12)/D) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose

• AUC from time zero to the last data point > LLOQ (lower limit of quantification) of BAY1163877 (AUC(0-tlast))

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• AUC(0-tlast) divided by dose (mg) per kg body weight (AUC(0-tlast) norm) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• AUC(0-tlast) divided by dose (mg) (AUC(0-tlast)/D) of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• AUC of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• AUCnorm of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• AUC/D of BAY1163877

  On cycle 1, Day 1 to 3 (single-dose): Pre- dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours post-dose

• Maximum Observed Drug Concentration in Plasma after multiple administrations (Cmax, md) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• Cmax after multiple administrations divided by dose (mg) per kg body weight (Cmax,norm, md) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• Cmax after multiple administrations divided by dose (mg) (Cmax/Dmd) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• AUC(0-12) after multiple administrations (AUC(0-12)md) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• AUC(0-12) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-12)norm,md) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• AUC(0-12) divided by dose (mg) after multiple administrations (AUC(0-12)/Dmd) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• AUC(0-tlast)after multiple administrations (AUC(0-tlast)md) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• AUC(0-tlast) after multiple administrations divided by dose (mg) per kg body weight (AUC(0-tlast) norm,md) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

• AUC(0-tlast) after multiple administrations divided by dose (mg) (AUC(0-tlast)/Dmd) of BAY1163877

  On cycle 1, Day 15 during multiple-dose: before morning dose and 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post-dose

Secondary Outcomes (4)

• Tumor response evaluation based on RECIST 1.1

  Screening, end of every second cycle (i.e., Cycle 2, 4, 6, 8,…)

• FGF23 levels

  Cycle 1 (Days 1 and 15)

• Phosphate levels

  Cycle 1 (Days 1, 8, 15), Cycle 2 to 12 (Days 1, 8, 15), Cycle ≥13 (Days 1, 11), end of treatment

• FGFR1/2/3 mRNA expression in tumor tissue to evaluate of biomarker status

  At Screening visit

Study Arms (1)

BAY1163877

EXPERIMENTAL

Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily

Drug: BAY1163877

Interventions

BAY1163877 DRUG

Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose. Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.

BAY1163877

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Japanese males or female aged ≥ 20 years
• Histologically or cytologically confirmed refractory, locally advanced or metastatic solid tumors who are not candidates for standard therapy at discretion of investigator
• High FGFR expression levels based on archival or fresh tumor biopsy specimen analysis. Bladder cancer subjects with low overall FGFR expression levels can be included if activating FGFR3 mutations are confirmed.
• Subjects must have at least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
• Life expectancy of at least 3 months
• Recovery to National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03 (CTCAE v4.03) Grade \< 2 level or recovery to baseline preceding the prior treatment from any previous drug / procedure-related toxicity (subjects with persistent alopecia, anemia, and/or hypothyroidism can be included)
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2
• Adequate bone marrow, liver and renal function
• Prothrombin time-International normalized ratio (PT-INR) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN. Subjects being treated with anticoagulant, e.g. warfarin or heparin, will be allowed to participate provided no prior evidence of an underlying abnormality in these parameters exists

You may not qualify if:

• History or current condition of an uncontrolled cardiovascular disease including congestive heart failure New York Heart Association (NYHA) \> Class 2, unstable angina (symptoms of angina at rest) or new-onset angina (within last 3 months) or myocardial infarction within past 6 months and cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted)
• Left ventricular ejection fraction (LVEF) \< 50% as assessed by echocardiography performed
• Subjects with history and/or current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis). Calcium (Ca) x (time) phosphate (PO4) should be \< 70 mg²/dL².
• Moderate or severe hepatic impairment (subjects with Child-Pugh score B or C cannot be included.)
• Known human immunodeficiency virus (HIV) infection
• Subjects with an active hepatitis B and/or C infection requiring treatment
• Anticancer chemotherapy or immunotherapy during the study or within 5-half-lives of anticancer chemotherapy or immunotherapy before start of study treatment.
• Systolic blood pressure ≤ 110 and pulse rate ≥ 100/min, or diastolic blood pressure ≤ 70 mmHg and pulse rate ≥ 100/min
• Uncontrolled hypertension as indicated by a resting systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg at screening

Sponsors & Collaborators

• Bayer: lead

Study Sites (2)

Unknown Facility

Kashiwa, Chiba, 277-8577, Japan

Location

Unknown Facility

Koto-ku, Tokyo, 135-8550, Japan

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Rogaratinib

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 29, 2015
• First Posted: October 30, 2015
• Study Start: December 15, 2015
• Primary Completion: February 5, 2017
• Study Completion: December 6, 2017
• Last Updated: April 18, 2018

Record last verified: 2018-04

Locations

JP (2)